Rhumbline Advisers Makes New $34,000 Investment in Mural Oncology plc (NASDAQ:MURA)

Rhumbline Advisers purchased a new position in Mural Oncology plc (NASDAQ:MURA) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,786 shares of the company’s stock, valued at approximately $34,000. Rhumbline Advisers owned about 0.06% of Mural Oncology at the end of the most recent reporting period.

Separately, Harbor Capital Advisors Inc. purchased a new position in Mural Oncology in the 2nd quarter worth about $115,000. 80.21% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Caroline Loew sold 12,531 shares of Mural Oncology stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $2.91, for a total transaction of $36,465.21. Following the transaction, the chief executive officer now directly owns 240,391 shares of the company’s stock, valued at approximately $699,537.81. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Mural Oncology Price Performance

NASDAQ MURA opened at $3.13 on Wednesday. Mural Oncology plc has a 1-year low of $2.88 and a 1-year high of $17.00. The business’s fifty day moving average price is $3.27 and its 200-day moving average price is $3.55.

Mural Oncology (NASDAQ:MURA) last announced its earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.90) by $0.04. Research analysts anticipate that Mural Oncology plc will post -7.54 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Rodman & Renshaw started coverage on shares of Mural Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $15.00 price target for the company.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.